Sharemaestro Newsreel

Earnings To Watch: Alpha Teknova Inc (TKNO) Q2 2026 -- GF Value Sees 24% Downside

Alpha Teknova Inc (TKNO) is preparing to release its Q2 2026 earnings, with revenue expected to hit $10.97 million and earnings at $-0.08 per share. While analyst estimates show an average price target implying a significant upside, GuruFocus's GF Value suggests a 24% downside …

Dr. Reddy's Laboratories Ltd $RDY Shares Purchased by Quantinno Capital Management LP

Roth/MKM initiates Alpha Teknova stock with buy rating on growth outlook

Roth/MKM has initiated coverage on Alpha Teknova Inc. (NASDAQ:TKNO) with a Buy rating and a $7.00 price target, citing the company's strong growth prospects and high customer retention. The firm highlighted Alpha Teknova's differentiated customizable solutions for the life sciences sector and the potential …

North Carolina pharmaceutical company laying off 47 in Hoover, leaving Birmingham area

BioCryst Pharmaceuticals, a biotechnology company based in Durham, North Carolina, is closing its Birmingham area facilities in Hoover and laying off 47 workers. This strategic move involves discontinuing internal discovery programs and shutting down its Discovery Center of Excellence, ending the company's decades-long research …

Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates

Elanco Animal Health (ELAN) reported strong Q2 2026 earnings, beating analyst estimates for both EPS and revenue. The company posted earnings of $0.34 per share against an estimate of $0.27, and revenues of $1.37 billion, surpassing the $1.24 billion expectation. Despite this positive performance, …

Pacira Q2 2026 earnings: Revenue rises as adjusted EBITDA declines

Pacira BioSciences reported a 6% revenue increase to $192.4 million in Q2 2026, yet adjusted EBITDA declined by approximately 10% and non-GAAP net income fell 18% due to rising expenses. The company also lowered its full-year revenue guidance following the divestiture of iovera°. Despite …

Pacira BioSciences, Inc. 2026: Revenue $192.4M, EPS $0.12— 10-Q Summary

Pacira BioSciences, Inc. reported strong financial results for the 2026 quarter, with revenue of $192.4M and diluted EPS of $0.12, showing significant growth compared to the prior year. Key drivers included increased net product sales for EXPAREL and ZILRETTA, expanded reimbursement for EXPAREL, and …

Perrigo Company Plc (PRGO) Stock Analysis: A Deep Dive Into Its 54.49% Potential Upside

Perrigo Company Plc (PRGO) presents a potential investment opportunity with an analyst-projected upside of 54.49%, despite recent declines from its 52-week high and current financial challenges. The company, a healthcare sector stalwart known for OTC health and wellness products, trades near its 52-week low. …

Zoetis (ZTS) Reports Q2: Everything You Need To Know Ahead Of Earnings

Earnings call transcript: Emergent BioSolutions Q2 2026 revenue tops guidance

This article provides the Q2 2026 earnings report for Emergent BioSolutions. It is a quarterly filing (10-Q) that details the company's financial performance during the second quarter of 2026.

United Therapeutics (UTHR) Earnings Date and Reports 2026 $UTHR

Perrigo (NYSE:PRGO) Shares Gap Up on Better-Than-Expected Earnings

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

Pacira BioSciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PCRX) 2026-08-05

Pacira BioSciences reported a 6% increase in Q2 2026 revenue to $192.4 million, driven by strong sales of EXPAREL, ZILRETTA, and iovera°. The company highlighted expanded payer coverage for EXPAREL and progress in its pipeline, while also completing the sale of iovera° to Zimmer …

SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday

Perrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates

Perrigo (NYSE:PRGO) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Emergent Biosolutions (NYSE:EBS) Announces Quarterly Earnings Results

Alpha Teknova (NASDAQ:TKNO) Issues Earnings Results, Beats Estimates By $0.02 EPS

BioCryst Pharmaceuticals (BCRX) Earnings Date and Reports 2026 $BCRX

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say

Elanco Animal Health Incorporated 2026 Q2 - Results - Earnings Call Presentation (NYSE:ELAN) 2026-08-05

Elanco Animal Health reported strong second-quarter 2026 results, exceeding prior guidance with revenue up 10% to $1.368 billion, driven by new pet-health products like Zenrelia and Credelio Quattro, and growth in U.S. farm animal operations. The company raised its full-year organic constant-currency revenue growth …

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

United Therapeutics Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:UTHR) 2026-08-05

United Therapeutics (UTHR) Stock Still Looks Cheap With Strong Returns Priced In

United Therapeutics (UTHR) Q2 Earnings Surpass Estimates

Enterprise value to EBITDA forward of Canopy Growth Corporation – MUN:11L

The article provides financial data on Canopy Growth Corporation (MUN:11L), specifically its Enterprise Value to EBITDA forward. It indicates that the market was closed with no trades at the time of publication and briefly lists the available financial tools and data sources on the …

Earnings To Watch: Lantheus (LNTH) Reports Q2 Results Tomorrow

Earnings call transcript: Cumberland Pharmaceuticals swings on Q2 2026 reset

Cumberland Pharmaceuticals announced a strategic shift in Q2 2026, selling its commercial brands to Apotex Health to transition into a biopharmaceutical development company. This transaction significantly strengthened its balance sheet with $100 million at closing and an estimated $108 million in total net proceeds, …

Takeda aims for dengue vaccine inclusion in India's shots program

Japanese drugmaker Takeda Pharmaceutical is seeking to integrate its newly approved dengue vaccine, Qdenga, into India's national immunization program. This move follows the vaccine's approval by India's Central Drugs Standard Control Organisation last month. The initiative aims to combat dengue fever, which infected 120,000 …

Is Pacira BioSciences Inc (PCRX) Undervalued After Q2 Earnings B

Weekly Recap: Hims & Hers data-sharing suit and FDA panel backs peptides

Hims & Hers (HIMS) is facing lawsuits from the FTC, Los Angeles County, and Utah over alleged data-sharing with Meta and Snap, as well as deceptive billing practices. Simultaneously, the company is exploring opportunities in the peptides market after an FDA advisory panel recommended …

Cumberland outlines over 5 years of runway following $1.50 per share special dividend

Earnings Call Insights: Cumberland Pharmaceuticals (CPIX) Q2 2026 MANAGEMENT VIEW * “In June, our shareholders overwhelmingly approved the strategic transaction with Apotex Health, on July 1st, we successfully closed the agreement to integrate our branded U.S. commercial businesses.” (Founder, Chairman, President & CEO A. …

NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Hims & Hers Health, Inc. (NYSE: HIMS) after the Federal Trade Commission filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following this news, HIMS's …

Xeris Biopharma President, COO Kevin McCulloch sells 15,000 shares for $120,240

Xeris Biopharma President and COO Kevin McCulloch sold 15,000 common shares for $120,240 on August 3, 2026, at a price of $8.02 per share. Following this transaction, his direct stake increased to 1,676,126 shares. The report also noted his spouse indirectly holds 25,000 shares.